Navigation Links
Fralex reaches 100th patient milestone in fibromyalgia study
Date:3/10/2008

- Interim analysis results expected in Q3 2008 -

TORONTO, March 10 /PRNewswire-FirstCall/ - Fralex Therapeutics Inc. (TSX:FXI) ("Fralex" or the "Company"), a medical technology company developing a non-invasive neuromodulation device, today announced the randomization of the 100th patient into the RELIEF study. RELIEF is a multi-centre, double-blind placebo-controlled randomized clinical trial designed to assess the safety and efficacy of Complex Neural Pulse (CNP(TM)) therapy for the relief of chronic pain associated with fibromyalgia.

The data from the first 100 patients will serve as input to an interim analysis ("IA") which will lead to a determination of the number of patients required - between 200 and 300 - to achieve statistical significance at the primary efficacy endpoint. Enrolment will not pause following the randomization of the 100th patient. The results of the IA are expected to be available in Q3 2008.

"The randomization of 100 patients into our pivotal RELIEF trial is a significant milestone for Fralex. Results of the interim analysis will allow us to predict the number of subjects required to achieve statistical significance," said Avi Grewal, President and CEO of Fralex. "We believe that our CNP therapy has the potential to be a safe and effective, non-drug, non-invasive treatment for pain associated with fibromyalgia. The information from the interim analysis will be critical for developing timelines for the commercialization of our CNP therapy."

The RELIEF trial is being conducted in the U.S. and Canada across 19 centres, under an Investigational Device Exemption ("IDE") from the U.S. FDA and an Investigational Testing Authorization ("ITA") from Health Canada. Patients are randomized on a one-to-one basis to receive CNP or placebo for 12 weeks. The primary efficacy endpoint will be a statistically significant difference between the active and placebo groups in the reduction of their Numerical Rating S
'/>"/>

SOURCE Fralex Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
2. Genmab Reaches Milestones in Ofatumumab Collaboration
3. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
4. Luminex Corporation Reaches Settlement With Rules Based Medicine, Inc.
5. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
6. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
7. CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
8. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
9. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Artromick Aligns with McKesson to Enhance Medication Safety at the Patients Bedside
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Streetsboro, Ohio (PRWEB) April 16, 2015 ... Safety Index, overexertion involving an outside source was ... injuries. This includes injuries related to lifting, pushing, ... $15.1 billion in direct costs. The David Round ... Round is committed to working hard to develop ...
(Date:4/16/2015)... recognition of World Hemophilia Day, Biogen  (NASDAQ: BIIB ... than 15 prominent landmarks red throughout the United ... Bridge and Prudential Tower, Chicago,s Wrigley ... Denver,s Coors Field . The ... coincide with hemophilia community events in a dozen locations across ...
(Date:4/16/2015)... - Bioenterprise Corporation is pleased to announce that it will ... , PEI.  Bioenterprise has established a 3-year strategic ... the commercialization of agricultural technologies and innovations. ... They have been at the heart of agri-innovation in ... Dave Smardon , President & CEO of Bioenterprise Corporation.  ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
Breaking Biology Technology:The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... with its goal of extending electronic government and ... how such a massive undertaking can take place ... sharing information and integrating systems has been clear ... , ,What has been missing is the organizational ...
... carefully established position as a nexus for research and development ... academic and other research institutions, according to a new report. ... This prediction comes from the Wisconsin Technology Council ... report, titled The Economic Value of Academic Research and Development ...
... Institutes of Health. Madison, Wis. ... Wednesday that it will receive a $1.26 million Phase II ... Health. , ,The funds will be used to help produce ... disorder that kills red blood cells. This results in a ...
Cached Biology Technology:State CIO wants to unify electronic government 2State CIO wants to unify electronic government 3State CIO wants to unify electronic government 4Economic report raises red flags on Wisconsin's future 2Economic report raises red flags on Wisconsin's future 3Mirus receives $1.26 million SBIR grant to combat anemia 2
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... assumed that if mercury is high and increasing in fish ... true of fish elsewhere in the Arctic. But a ... discovered that assumption is wrong in much of the continental ... a result of diverse atmospheric, geological, and biological conditions, "It ...
... developed a new vaccine that protects against lethal pneumonia ... drug-resistant strains like MRSA. The research team was ... in the UI Carver College of Medicine. The findings ... Infectious Disease . The new vaccine targets toxins ...
... , a sprawling shrub that grows on just a single ... in its family and genus. It is also one of ... 200 million years ago. Now, researchers from Indiana University, with ... Penn State University, and the Institute of Research for Development ...
Cached Biology News:Virginia Tech research overturns assumption about mercury in the Arctic 2Virginia Tech research overturns assumption about mercury in the Arctic 3Staph stoppers 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 3
...
... The Luminex 200 IS System is ideal ... Upstate's Beadlyte reagents. This system contains the ... developed by Luminex. The user can design ... kits. The system has fully integrated graphing ...
... Quality ISO 9001:2000 Certified USDA Research ... Validated, SOP's Training AALAS Certified ... All Procedures GLP Documentation Upon Request ... shopping point for all your custom immunology ...
... Re-Blot Western Blot Recycling Kit is ... Western blots that have been developed ... other isotopes. It is not recommended ... 4-chloronapthol, etc.), as it is not ...
Biology Products: